Sysmex (OTCMKTS:SSMXY) Updates FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Stock Performance

SSMXY traded down $0.06 on Thursday, reaching $18.22. The company had a trading volume of 75,584 shares, compared to its average volume of 84,987. The company’s fifty day moving average is $18.86 and its 200 day moving average is $19.02. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.42 and a current ratio of 3.19. The stock has a market cap of $11.47 billion, a P/E ratio of 36.91 and a beta of 0.90. Sysmex has a fifty-two week low of $14.38 and a fifty-two week high of $28.58.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.17 EPS for the quarter. As a group, analysts predict that Sysmex will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.